Evidence map›Paper›PMID 33790638›Full record

ArticleInternational journal of general medicine2021

Variants in

Mansour A Alghamdi, Laith Al-Eitan, Rami Alkhatib, Ahmad Al-Assi, Ayah Almasri, Hanan Aljamal, Hatem Aman, Rame Khasawneh

Open access · goldAbstract read
In one paragraph

Article in International journal of general medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Mansour A AlghamdiDepartment of Anatomy, College of Medicine, King Khalid University, Abha, 61421, Saudi Arabia.ORCID 0000-0002-6613-1498
Laith Al-EitanDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, 22110, Jordan.ORCID 0000-0003-0064-0190
Rami AlkhatibDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, 22110, Jordan.ORCID 0000-0003-1635-8624
Ahmad Al-AssiFaculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan.ORCID 0000-0003-2245-6191
Ayah AlmasriDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Hanan AljamalDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, 22110, Jordan.ORCID 0000-0002-6660-3352
Hatem AmanDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Rame KhasawnehDepartment of Hematopathology, King Hussein Medical Center (KHMC), Royal Medical Services (RMS), Amman, 11118, Jordan.ORCID 0000-0002-6716-2851
Jordan University of Science and Technology · JOKing Hussein Medical Center · JOKing Khalid University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWarfarin has been in use for more than 60 years; however, it has serious side effects including major bleeding. The high interpatient variability in the required dose impacts the sensitivity and responsiveness to warfarin in different patients. This study aims to assess the influence of

methodsThis study was conducted in the anti-coagulation clinic in Queen Alia Heart Institute in Amman, with 212 patients in total. Three SNPs were genotyped within

resultsOur findings revealed that patients with LTA polymorphism are more prone to warfarin sensitivity than others. Furthermore, carriers of the LTA polymorphism needed a lower initial dose of warfarin and are associated with less variation in doses required to achieve target INR.

conclusionThe current study could help in understanding the role of genetic variability in warfarin dosing and matching patients to different treatment options. Clinical applications of these findings for warfarin treatment may also contribute to improving the efficacy and safety of warfarin treatment in Jordanian patients with cardiovascular disease.

Indexed as

INRpharmacogeneticssingle nucleotide polymorphismsstrokewarfarin

Identifiers

PMID33790638
PMCPMC8006967
OpenAlexW3138035369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.